The duration of life after chemotherapy for patients with lymphoma is the same as the prognosis of lymphoma. Because lymphoma is divided into inert and highly malignant, long-term survival is better in patients with inert lymphoma. For example, patients with chronic lymphocytic leukemia, follicular lymphoma, and marginal zone lymphoma have a five-year survival rate of 70%-80% after standard treatment. However, for highly malignant and aggressive lymphomas, such as T-lymphoblast lymphoma, highly aggressive B-cell lymphoma, or diffuse large B-lymphoma, the prognosis of such patients is poorer and their sensitivity to chemotherapy is poorer. Therefore, newer and more effective chemotherapy regimens will be investigated for these patients, and if complete remission is achieved with chemotherapy, autologous stem cell transplantation will be recommended to consolidate the therapeutic effect of chemotherapy.